PRTA

Prothena Corp PLC (PRTA) | Rumor.io

Prothena

PRTA

Attention (50-day avg)0%

Attention rank (50-day avg)#3,234

Bullish sentiment (50-day avg)0%

Price to earnings ratio-1.93

Market capitalization447.7M

Earnings per share-0.82

Dividend yield (TTM)2.29%

Revenue (annual)9.7M

Net income (annual)-244.1M

Social

What share of all stock conversation is about PRTA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

May 27

$PRTA has dropped 22.5% after halting birtamimab development due to the AFFIRM-AL study not hitting its primary endpoint for AL amyloidosis.
Analysts remain optimistic, with 6x buy ratings and price targets ranging from $18 to $110, indicating potential for future growth.
Prothena Corporation's operating expenses may be reduced as a result of the development halt, potentially impacting the company's financial situation.

Generated by AI

Sentiment

Of the messages about PRTA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	0%	0%	52.86% -15.53
Bearish	—	100%	100%	47.14% +15.53

Bullish· Oct 16

$PRTA is experiencing high trading volume, with trades 416% and 324% above average volume, resulting in a 16.80% and 22.84% price increase.
The stock has a bullish technical setup, with a D1/W1 bullish flip and a potential M15 OR $5 extension.
Prothena Corporation plc is exploring strategic options, including a potential sale or partnership, which has led to a 21.7% increase in $PRTA shares.

Bearish· Oct 7

The stock may gap down on Monday, potentially breaking below the 40s level.
The stock's refusal to have a red day despite being oversold for 7 trading days suggests that it may be artificially propped up by market makers.
The stock's price may not drop significantly until after earnings, when analysts typically reverse their trend predictions and the options market is cleared.

Generated by AI

Topics

Of the messages about PRTA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	65.31%
Earnings	—	—	0%	2.62%
Analysts	—	—	0%	6.12%
Controversies	—	—	0%	23.62%
Macro	—	—	0%	0.58%
Technical Analysis	—	—	0%	1.75%

Earnings· Feb 14

Prothena Corporation plc ($PRTA) reported a loss of $1.24, beating consensus estimates by $0.20.
The company missed revenue estimates, reporting $0.23 million in revenue.
Prothena Corporation plc beat EPS loss estimates by $0.24 and the Estimize EPS consensus by 18 cents.

Analysts· Jul 13

Analysts at HC Wainwright & Co. maintain a Buy rating for Prothena Corp ($PRTA) with a price target of $75.
Citigroup analyst Neena Bitritto-Garg maintains a Buy rating for Prothena Corp ($PRTA) with a price target of $72.
Oppenheimer analyst Jay Olson maintains an Outperform rating for Prothena Corp ($PRTA) with a price target of $76.

Announcements· Sep 28

Prothena Corporation plc's stock price is rising due to positive results from a late-stage study for treating Alzheimer's disease by Biogen and Eisai.
Bank of America Co. has upgraded Prothena's stock rating to buy.
Prothena's stock is also being boosted by speculation that Biogen may be interested in acquiring the company.

Generated by AI

Community

Of the messages about PRTA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	46.67%	29.02%
Newcomers	—	100%	53.33%	70.98%

Regulars· Oct 16

Prothena Corporation plc may be preparing for a potential sale ahead of key Alzheimer's drug data, according to a report.
The company's stock price has been volatile, with a 22.84% increase and trading 324% above average volume, possibly due to speculation about a sale.
Prothena's Alzheimer's treatment is expected to report readout data soon, which could impact the stock price, with some investors re-entering the market after previously selling their shares.

Newcomers· Oct 16

$PRTA shares are expected to be sold or partnered with due to strategic options being explored, according to Bloomberg.
The stock has been halted for the first time, with a 21.7% increase, amid rumors of a potential sale or partnership.
Prothena Corporation plc is developing a closely-watched treatment for Alzheimer's disease, which is expected to be released in the coming months.

Generated by AI

News

Prothena Corp Public Ltd Insider Bought Shares Worth $843,460, According to a Recent SEC Filing

William P Scully, 10% Owner, on September 18, 2026, executed a purchase for 100,000 shares in Prothe

8d agoYahoo Finance

RBC Capital Keeps Their Hold Rating on Prothena (PRTA)

Tipranks Press Release.

1mo agotheglobeandmail.com

PRTA's Q2 Loss Narrower Than Expected, Pipeline Progress in Focus

Prothena beat adjusted Q2 loss estimates, reaffirmed 2026 cash-use guidance and highlights partner pipeline progress as a key milestone decision nears.

1mo agoYahoo Finance

Prothena (PRTA) Reports Q2 Loss, Misses Revenue Estimates

1mo agoYahoo Finance

Prothena: Q2 Earnings Snapshot

1mo agoYahoo Finance

Prothena Reports Second Quarter 2026 Financial Results and Business Highlights

DUBLIN, August 06, 2026--Prothena reported financial results for the second quarter and first six months of 2026 and provided business highlights.

1mo agoYahoo Finance

Also Discussed

Investors talking about PRTA also mention

#	Name	Attention
1	Acumen Pharmaceuticals, Inc.ABOS	0%new
2	Theravance Biopharma Inc.TBPH	0%new
3	Agios Pharmaceuticals, Inc.AGIO	0%0
4	FOLD - Amicus Therapeutics, Inc.	——
5	Ultragenyx Pharmaceutical Inc.RARE	0.01%+0.01
6	Ionis Pharmaceuticals, Inc.IONS	0%new
7	Biogen IncBIIB	0%-0.01
8	EGRX - Eagle Pharmaceuticals, Inc.	——
9	Acadia Pharmaceuticals Inc.ACAD	0%+0
10	BLCM - Bellicum Pharmaceuticals, Inc.	——

Prothena Corp PLC

Healthcare
Biotechnology

Prothena Corp PLC is a clinical-stage biotechnology company focused on discovering and developing therapies for diseases linked to protein dysregulation. The company’s current work centers on investigational treatments for neurodegenerative disorders and rare peripheral amyloid diseases, areas where misfolded proteins play a critical role in disease progression. Its pipeline includes both wholly owned and partnered programs aimed at conditions such as Alzheimer’s disease, Parkinson’s disease, AL amyloidosis, and ATTR amyloidosis. Prothena Corp PLC also applies its proprietary scientific platform to investigate targeted biologic therapies designed to address complex disease pathways in the brain and peripheral tissues. Headquartered in Dublin, Ireland, Prothena Corp PLC plays a specialized role in the biotechnology market by advancing experimental medicines for serious disorders with limited treatment options.

Website

Location

77 Sir John Rogerson’s Quay

Dublin, D02 VK60

Ireland

Social

What share of all stock conversation is about PRTA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

May 27

$PRTA has dropped 22.5% after halting birtamimab development due to the AFFIRM-AL study not hitting its primary endpoint for AL amyloidosis.
Analysts remain optimistic, with 6x buy ratings and price targets ranging from $18 to $110, indicating potential for future growth.
Prothena Corporation's operating expenses may be reduced as a result of the development halt, potentially impacting the company's financial situation.

Generated by AI

Sentiment

Of the messages about PRTA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	0%	0%	52.86% -15.53
Bearish	—	100%	100%	47.14% +15.53

Bullish· Oct 16

$PRTA is experiencing high trading volume, with trades 416% and 324% above average volume, resulting in a 16.80% and 22.84% price increase.
The stock has a bullish technical setup, with a D1/W1 bullish flip and a potential M15 OR $5 extension.
Prothena Corporation plc is exploring strategic options, including a potential sale or partnership, which has led to a 21.7% increase in $PRTA shares.

Bearish· Oct 7

The stock may gap down on Monday, potentially breaking below the 40s level.
The stock's refusal to have a red day despite being oversold for 7 trading days suggests that it may be artificially propped up by market makers.
The stock's price may not drop significantly until after earnings, when analysts typically reverse their trend predictions and the options market is cleared.

Generated by AI

Topics

Of the messages about PRTA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	65.31%
Earnings	—	—	0%	2.62%
Analysts	—	—	0%	6.12%
Controversies	—	—	0%	23.62%
Macro	—	—	0%	0.58%
Technical Analysis	—	—	0%	1.75%

Earnings· Feb 14

Prothena Corporation plc ($PRTA) reported a loss of $1.24, beating consensus estimates by $0.20.
The company missed revenue estimates, reporting $0.23 million in revenue.
Prothena Corporation plc beat EPS loss estimates by $0.24 and the Estimize EPS consensus by 18 cents.

Analysts· Jul 13

Analysts at HC Wainwright & Co. maintain a Buy rating for Prothena Corp ($PRTA) with a price target of $75.
Citigroup analyst Neena Bitritto-Garg maintains a Buy rating for Prothena Corp ($PRTA) with a price target of $72.
Oppenheimer analyst Jay Olson maintains an Outperform rating for Prothena Corp ($PRTA) with a price target of $76.

Announcements· Sep 28

Prothena Corporation plc's stock price is rising due to positive results from a late-stage study for treating Alzheimer's disease by Biogen and Eisai.
Bank of America Co. has upgraded Prothena's stock rating to buy.
Prothena's stock is also being boosted by speculation that Biogen may be interested in acquiring the company.

Generated by AI

Community

Of the messages about PRTA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	46.67%	29.02%
Newcomers	—	100%	53.33%	70.98%

Regulars· Oct 16

Prothena Corporation plc may be preparing for a potential sale ahead of key Alzheimer's drug data, according to a report.
The company's stock price has been volatile, with a 22.84% increase and trading 324% above average volume, possibly due to speculation about a sale.
Prothena's Alzheimer's treatment is expected to report readout data soon, which could impact the stock price, with some investors re-entering the market after previously selling their shares.

Newcomers· Oct 16

$PRTA shares are expected to be sold or partnered with due to strategic options being explored, according to Bloomberg.
The stock has been halted for the first time, with a 21.7% increase, amid rumors of a potential sale or partnership.
Prothena Corporation plc is developing a closely-watched treatment for Alzheimer's disease, which is expected to be released in the coming months.

Generated by AI

Prothena

Social

May 27

Bullish· Oct 16

Bearish· Oct 7

Earnings· Feb 14

Analysts· Jul 13

Announcements· Sep 28

Regulars· Oct 16

Newcomers· Oct 16

Prothena Corp Public Ltd Insider Bought Shares Worth $843,460, According to a Recent SEC Filing

RBC Capital Keeps Their Hold Rating on Prothena (PRTA)

PRTA's Q2 Loss Narrower Than Expected, Pipeline Progress in Focus

Prothena (PRTA) Reports Q2 Loss, Misses Revenue Estimates

Prothena: Q2 Earnings Snapshot

Prothena Reports Second Quarter 2026 Financial Results and Business Highlights

Also Discussed

Prothena Corp PLC

Company Information

Location

Prothena Corp Public Ltd Insider Bought Shares Worth $843,460, According to a Recent SEC Filing

RBC Capital Keeps Their Hold Rating on Prothena (PRTA)

PRTA's Q2 Loss Narrower Than Expected, Pipeline Progress in Focus

Prothena (PRTA) Reports Q2 Loss, Misses Revenue Estimates

Prothena: Q2 Earnings Snapshot

Prothena Reports Second Quarter 2026 Financial Results and Business Highlights

Also Discussed

Social

May 27

Bullish· Oct 16

Bearish· Oct 7

Earnings· Feb 14

Analysts· Jul 13

Announcements· Sep 28

Regulars· Oct 16

Newcomers· Oct 16